NASDAQ:ALKSAlkermes Stock Price, Forecast & News

Alkermes' stock was trading at $16.25 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, ALKS shares have increased by 12.0% and is now trading at $18.20.
View which stocks have been most impacted by Coronavirus.

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alkermes in the last year. There are currently 1 sell rating, 8 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Alkermes.

Alkermes is scheduled to release its next quarterly earnings announcement on Wednesday, October 28th 2020.
View our earnings forecast for Alkermes.

Alkermes Plc (NASDAQ:ALKS) released its quarterly earnings data on Wednesday, July, 29th. The company reported $0.06 earnings per share for the quarter, beating analysts' consensus estimates of ($0.13) by $0.19. The company earned $247.53 million during the quarter, compared to analysts' expectations of $232.70 million. Alkermes had a positive return on equity of 4.47% and a negative net margin of 10.87%. The business's revenue was down 11.6% on a year-over-year basis. During the same quarter last year, the firm posted $0.09 earnings per share.
View Alkermes' earnings history.

Alkermes issued an update on its FY20 earnings guidance on Wednesday, July, 29th. The company provided earnings per share guidance of $0.00-0.19 for the period, compared to the Thomson Reuters consensus EPS estimate of $0.11. The company issued revenue guidance of $965-1.005 billion, compared to the consensus revenue estimate of $983.05 million.

10 Wall Street analysts have issued 1-year price objectives for Alkermes' stock. Their forecasts range from $15.00 to $28.00. On average, they anticipate Alkermes' stock price to reach $19.80 in the next year. This suggests a possible upside of 8.8% from the stock's current price.
View analysts' price targets for Alkermes.

News stories about ALKS stock have trended negative recently, InfoTrie Sentiment Analysis reports. InfoTrie rates the sentiment of press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Alkermes earned a daily sentiment score of -2.6 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the near future.
View the latest news about Alkermes.

Alkermes saw a increase in short interest during the month of January. As of January 31st, there was short interest totaling 6,090,000 shares, an increase of 14.3% from the January 15th total of 5,330,000 shares. Based on an average daily volume of 1,580,000 shares, the days-to-cover ratio is presently 3.9 days. Currently, 3.9% of the company's stock are sold short.
View Alkermes' Short Interest.

Some companies that are related to Alkermes include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), BioMarin Pharmaceutical (BMRN), Incyte (INCY), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Immunomedics (IMMU) and Novavax (NVAX).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Alkermes investors own include Netflix (NFLX), AbbVie (ABBV), Gilead Sciences (GILD), NVIDIA (NVDA), Celgene (CELG), Pfizer (PFE), Starbucks (SBUX), Alibaba Group (BABA), Advanced Micro Devices (AMD) and Intel (INTC).

Alkermes trades on the NASDAQ under the ticker symbol "ALKS."

Alkermes' stock is owned by many different retail and institutional investors. Top institutional shareholders include First Trust Advisors LP (2.52%), UBS Group AG (1.24%), Russell Investments Group Ltd. (0.50%), Meditor Group Ltd (0.47%), Macquarie Group Ltd. (0.24%) and Swiss National Bank (0.22%). Company insiders that own Alkermes stock include David Joseph Gaffin, David W Anstice, Iain Michael Brown, Michael J Landine, Nancy Wysenski, Paul J Mitchell and Richard F Pops.
View institutional ownership trends for Alkermes.

ALKS stock was sold by a variety of institutional investors in the last quarter, including Meditor Group Ltd, Rhenman & Partners Asset Management AB, Alps Advisors Inc., New York State Common Retirement Fund, Amalgamated Bank, and Arizona State Retirement System. Company insiders that have sold Alkermes company stock in the last year include Iain Michael Brown, Michael J Landine, and Richard F Pops.
View insider buying and selling activity for Alkermes.

ALKS stock was acquired by a variety of institutional investors in the last quarter, including UBS Group AG, First Trust Advisors LP, MERIAN GLOBAL INVESTORS UK Ltd, WINTON GROUP Ltd, Russell Investments Group Ltd., Principal Financial Group Inc., Hardman Johnston Global Advisors LLC, and Platinum Investment Management Ltd..
View insider buying and selling activity for Alkermes.

Shares of ALKS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of ALKS stock can currently be purchased for approximately $18.20.

Alkermes has a market capitalization of $2.89 billion and generates $1.17 billion in revenue each year. The company earns $-196,620,000.00 in net income (profit) each year or $0.07 on an earnings per share basis. Alkermes employs 2,235 workers across the globe.

The official website for Alkermes is www.alkermes.com.

Alkermes' mailing address is 1 BURLINGTON ROAD CONNAUGHT HOUSE, DUBLIN L2, DUBLIN 4. The company can be reached via phone at 353-1772-8000 or via email at [email protected]